News – Page 973 – Endpoints News

Popular FDA commish Scott Gottlieb has handed in his resignation

7 years ago

Was AstraZeneca CEO Pascal Soriot happy with his $14.8M in '18 compensation? Probably not so much

7 years ago

The drug pricing debate in America reaches a boiling point at #JPM19

7 years ago

Pfizer stokes rumor mill with plan to raise $5B in debt; Lilly's CGRP Emgality wins speedy review for cluster ...

7 years ago

Citing lingering concerns, FDA stops Evoke at the 10-yard line a month before PDUFA date

7 years ago

With eye on Heron's rival product, Pacira to buy MyoScience to fortify its Exparel franchise

7 years ago

With $1.4B bet riding on their decision, myelofibrosis drug left for dead by Sanofi hits FDA's inside track to a ...

7 years ago

Bad year at Celgene? Forget about it. CEO Mark Alles nabbed a big raise as compensation gyrated to $16.2M

7 years ago

Bone marrow transplant sparks long-term remission in second HIV patient, renewing hope for a cure

7 years ago

Backed with $180M-plus in cash, I/O trailblazer Lieping Chen spotlights NextCure's preclinical work on next-gen ...

7 years ago

Senators seek changes to FDA guidance to speed entry of insulin biosimilars

7 years ago

Building on momentum from positive diabetes data, Zafgen scoops Biogen alum Priya Singhal as head of R&D

7 years ago

As scrutiny into drug prices intensifies, Lilly launches half price Humalog; BioXcel, Nektar expand collab to include ...

7 years ago

Vertex’s 3-year feud with NICE is about to come to a head as CEO Leiden heads to London

7 years ago

In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data

7 years ago

Team building. Pipeline revamp. Forward thrust. What does a decade of deals at Gilead tell us about Daniel ...

7 years ago

Ascendis Pharma offers positive surprise as its tech not just equals, but improves outcomes in key study

7 years ago

After nebulizer flop, Verona touts interim PhII results on another version of its lead COPD drug

7 years ago

Appetite for gene therapies gains momentum, as Biogen plans $800M buyout of Nightstar Therapeutics

7 years ago

Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field

7 years ago

ReViral taps Seth Hetherington to guide upcoming PhIIa; Incyte, Aquinox execs move to AI shop Notable Labs

7 years ago

The EMA officially vacates its London HQ — next stop Amsterdam; CHMP backs approval of 8 drugs

7 years ago

Abpro bags $60M in near-term R&D cash in tie-up with China's NJCTTQ, with eyes on bispecific T cell engagers

7 years ago

ImmunoGen's lead armed antibody falters in key ovarian cancer test as a monotherapy — shares crash

7 years ago

First page Previous page 970 971 972973974 975 976 Next page Last page